Japanese Encephalitis Virus Vaccine

From Anvita Health Wiki

Contents 1 Classification 2 Indications 3 Contraindications 4 Dosage 5 Mechanism-of-action 6 More General Terms 7 Additional Terms 8 References

Classification

• JE-MB ( JE-VAX)

• licensed in 1992
• production discontinued in 2006
• only vaccine available for children
• remaining does reserved for children

• J- VC ( IXIARO) [2]

• licensed in 2009 b0 adults >= 17 years of age

Indications

• active immunization against Japanese encephalitis for patients spending a month or longer in endemic or epidemic areas during season of transmission

Contraindications

• hypersensitivity to JE-VAX, especially manifesting as generalized urticaria or angioedema
• hypersensitivity to rodent proteins or proteins of neural origin
• hypersensitivity to thimerosal
• pregnancy, unless substantial risk of infection Warnings: not recommended for infants < 1 year of age Adverse reactions:

• most common (1-10%)

• inflammation at injection site, fever, headache, malaise, rash, chills, dizziness, myalgias, nausea/vomiting, abdominal pain, urticaria, pruritis, hypotension

• uncommon (< 1%)

• anaphylaxis, encephalitis, encephalopathy, seizure, peripheral neuropathy, erythema multiforme, erythema nodosum, angioedema, dyspnea, joint swelling

• adverse effects may occur shortly after or up to 17 days following vaccination
• report allergic or unusual adverse effects to: Vaccine Adverse Event Reporting System ( VAERS) (800) 822-7967

Dosage

• J- VC ( IXIARO) licensed in 2009 [2]

• adults >= 17 years of age
• two intramuscular injections one month apart

• JE-MB ( JE-VAX)

• adults & children > 3 years of age

• three doses of 1 mL on days 0, 7, & 14-30
• last dose 10 days before travel
• booster may be given 2 years after primary immunization

• children 1-3 years of age: 0.5 mL doses

Mechanism-of-action

• both vaccines are inactivated & stimulate production of neutralizing antibody

More General Terms

• vaccine

Additional Terms

• Japanese encephalitis virus

References

1. Kaiser Permanente Northern California Regional Drug Formulary, 1998
2. Fischer M et al. Japanese encephalitis vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2010 Mar 12;59(RR-1):1-27. PMID: [1]
3. National Guideline Clearinghouse Japanese encephalitis vaccines. Recommendations of the Advisory Committee on Immunization Practices (ACIP). ngc-guideline: [2]

Japanese encephalitis virus vaccine (JE-VAX, Ixiaro)